Options Prospectus
Released
Released
Announcement PDF
ALTERITY THERAPEUTICS LIMITED
[ACN 080 699 065]
(“the Company”)
OPTIONS PROSPECTUS
This prospectus (Prospectus) contains the following offers of options (New Options) (each with an
exercise price of A$0.028 (2.8 Australian cents), expiry date of 26 February 2027 and which, upon
exercise, entitle the holder to one fully paid ordinary share in the capital of the Company (Share):
•
1,212,121,223 New Options to participants in the Placement (as defined in Section 1.2 of this
Prospectus) on the basis as described in Section 1.1 of this Prospectus (Placement Offer); and
•
10,179,688 New Options to MST Financial Services Pty Ltd (MST Financial) (and/or its
nominee(s)) for the purpose described in section 1.1 of this Prospectus (Broker Offer).
The Placement Offer and Broker Offer are collectively the Offers. The issue of the New Options was
approved by the shareholders of the Company at the general meeting on 31 March 2025 (Meeting).
The Offers are only made to and capable of acceptance by the respective identified parties. Further
details of the Offers are contained within this Prospectus.
Unless closed earlier the Offers close at 7:00pm (Melbourne time) on 22 April 2025, which date may
change without notice.
THIS DOCUMENT IS IMPORTANT AND SHOULD BE READ IN ITS ENTIRETY
It is important that you read this Prospectus carefully before deciding whether to accept an Offers
(or any of them). If you do not understand its contents you should consult your stockbroker,
accountant or other professional adviser.
The securities offered under this Prospectus are considered highly speculative
-2CORPORATE DIRECTORY
ALTERITY THERAPEUTICS LIMITED
[ACN 080 699 065]
Directors
Geoffrey Kempler - Non-Executive Chairman
Lawrence Gozlan - Non-Executive Director
Peter Marks - Non-Executive Director
Brian Meltzer - Non-Executive Director
Chief Executive Officer
David Stamler
Company Secretary and Chief Financial Officer
Abby Macnish Niven
Registered Office
Level 14, 350 Collins Street
Melbourne VIC 3000
Tel: +61 3 9349 4906
Share Registrar (named for information purposes only)
Automic Pty Ltd
Level 5, 191 St Georges Terrace
Perth WA 6000
ASX Code
ATH
Web Site
www.alteritytherapeutics.com
To view annual reports, shareholder and company information, news announcements, background information
on the Company’s business and historical information, visit https://alteritytherapeutics.com/.
-3IMPORTANT NOTICES
This prospectus (Prospectus) is dated 17 April 2025. A copy of this Prospectus was lodged with the Australian
Securities & Investments Commission (ASIC) on the same date. Neither ASIC nor ASX Limited (ASX) nor their
respective officers take any responsibility as to the contents of this Prospectus.
Subject to the Corporations Act 2001 (Cth) (Corporations Act), the ASX Listing Rules and other applicable laws,
the Company reserves the right to close the Offers (or either of them) early, to extend the Closing Date in
respect of one or both of the Offers and/or any other dates (by making an announcement of the extension to
ASX), or not to proceed with the Offers (or either of them).
Unless closed earlier, the Offers close at 7:00pm (Melbourne time) on 22 April 2025 (Closing Date), which
date may change, in respect of one or both of the Offers, without notice.
This Prospectus is for offers of options to acquire continuously quoted securities (the New Options) and
accordingly is not required by the Corporations Act to contain all the information normally required to be set
out in a document of this type. This Prospectus contains and applies to the Offers of New Options.
This Prospectus incorporates by reference certain information contained in documents lodged with ASIC. A
document incorporated by reference in this Prospectus in this manner may be obtained free of charge from
the Company during the application period.
The Company has adopted a target market determination (TMD) for each of the respective Offers. The TMDs
are available at the website of the Company, www.alteritytherapeutics.com. By making an application under
one or both of the Offers, an investor warrants that they have read and understood the applicable TMD and
that they meet the eligibility criteria of, and fall within the target markets set out in, that TMD.
No person is authorised to give any information or make any representation in connection with this Prospectus
that is not contained in this Prospectus. Any information or representation not so contained may not be relied
on as having been authorised by the Company in connection with the offer of securities.
This Prospectus does not constitute an offer in any place in which, or to any person to whom, it would not be
lawful to make such an offer. The distribution of this Prospectus in jurisdictions outside Australia may be restricted
by law and persons who come into possession of this Prospectus should observe any of those restrictions. Any
failure to comply with the restrictions may constitute a violation of applicable securities law.
No action has been taken to register or qualify the Offers or the New Options or otherwise to permit a public
offering of the securities offered under this Prospectus, in any jurisdiction outside Australia.
The New Options have not been, and will not be, registered under the United States Securities Act of 1933 and
should not be offered or sold within the USA.
No account has been taken of particular objectives, financial situation or needs of recipients of this Prospectus.
Recipients of this Prospectus should have regard to their own objectives, financial situation and needs. Recipients
of this Prospectus should make their own independent investigation and assessment of the Company, its business,
assets and liabilities, prospects and profits and losses, and risks associated with investing. Independent expert
advice should be sought before any decision is made to apply for New Options under this Prospectus.
All monetary amounts in this Prospectus are in Australian dollars unless otherwise stated.
All dates and times are dates and times in Melbourne, Victoria, Australia unless otherwise stated.
The securities offered under this Prospectus are considered highly speculative.
-4TIMETABLE^
Lodgement of Prospectus
17 April 2025
Opening date of Offers
17 April 2025
Closing Date of the Offers at 7.00pm (Melbourne time), unless closed earlier
22 April 2025
Proposed issue of New Options
23 April 2025
^ The above dates should be regarded as indicative only and may change without notice. All dates and times
are Melbourne, Victoria, Australia time. Subject to the Corporations Act, the ASX Listing Rules and other
applicable laws, the Company reserves the right, in respect of either or both Offers, to change the above dates,
close the Offers (or either of them) before the date stated above, accept late applications under the Offers (or
either of them), extend the Closing Date in respect of one or both Offer or not proceed with the Offers (or either
of them). The Company reserves the right to extend the Closing Date in respect of one or both of the Offers by
making an announcement of the extension to ASX. No securities will be issued on the basis of this Prospectus
after 17 May 2026, being the expiry date of this Prospectus.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
CONTENTS
Details of the Offers.....................................................................................................................9
Purpose of the Offers and this Prospectus ................................................................................10
Financial effect of the Offers .....................................................................................................10
Effect on Control and the Capital Structure of the Company....................................................10
Risks ...........................................................................................................................................12
Acceptance Instructions ............................................................................................................15
Continuous Disclosure Obligations ............................................................................................15
ASX Announcements .................................................................................................................16
Terms of securities offered ........................................................................................................18
Director’s interests ....................................................................................................................19
Taxation .....................................................................................................................................21
Overseas Investors.....................................................................................................................21
Privacy........................................................................................................................................21
Electronic Prospectus ................................................................................................................21
Investment Decisions.................................................................................................................22
Future Performance...................................................................................................................22
Enquiries ....................................................................................................................................22
-5KEY INVESTMENT RISKS – SUMMARY
Please read and consider this Prospectus in full and in conjunction with matters which have or may be referred
to in the Company’s ASX announcements before applying for New Options.
Section 5 of this Prospectus contains an overview of some of the key risks associated with investment in the
Company, including risks associated with the Offers as set out below:
•
Value of securities and share market conditions including liquidity risk.
•
Potential taxation consequences.
•
There being no guarantee that the share price of the Company will be greater than the exercise price of
New Options prior to the expiry date of New Options.
The Company provided detailed disclosure of business risk factors in its item 3.D of its 2024 Annual Report for
the reporting period ended 30 June 2024 that was released to ASX on 26 September 2024. The 2024 Annual
Report has been lodged with ASIC and item 3.D of the 2024 Annual Report is incorporated by reference into
this Prospectus in accordance with Section 712 of the Corporations Act.
A copy of the 2024 Annual Report including item 3.D is available at www.asx.com.au (search code “ATH”) and
can be obtained from the Company upon request.
A selection of risk factors as described in item 3.D of the 2024 Annual Report are set out below:
(a)
The Company has a history of operating losses.
(b)
The Company relies on research institutions to conduct its clinical trials and may not be able to secure
and maintain research institutions to conduct future trials. The institutions that the Company works with
have their own limits and procedures that influence or limit the Company’s ability to conduct research
and development and conduct of clinical trials. The Company’s reliance on these research institutions
provides it with less control over the timing and cost of clinical trials, clinical study management
personnel and the ability to recruit subjects.
(c)
If the Company does not obtain the necessary governmental approvals, it will be unable to develop or
commercialise its pharmaceutical products.
(d)
The Company’s success depends upon its ability to protect its intellectual property and its proprietary
technology, to operate without infringing the proprietary rights of third parties and to obtain marketing
exclusivity for its products and technologies.
(e)
The Company’s business and operations would suffer in the event of any IT system failure, cybersecurity
attack, data breach, or vulnerability in the Company’s or a third-party vendors’ information security
program or defences.
(f)
The Company is currently operating in a period of economic uncertainty and capital markets disruption,
which has been significantly impacted by geopolitical instability due to the ongoing military conflicts
such as in the Middle East and between Russia and Ukraine.
(g)
The Company consider proprietary trade secrets and/or confidential know-how and unpatented knowhow to be important to its business.
(h)
The Company’s research and development efforts will be seriously jeopardised if it is unable to retain
key personnel and cultivate key academic and scientific collaborations.
(i)
The testing, marketing and sale of human health care products also entails an inherent risk of product
liability.
-6(j)
The biotechnology and pharmaceutical industries are subject to rapid and significant technological
change. The Company’s competitors are numerous and include major pharmaceutical companies,
biotechnology firms, universities and other research institutions.
Further details of the above risk factors, as well as information regarding additional business risk factors that
may impact upon the Company, are set out in item 3.D of the 2024 Annual Report as described above.
-7ABOUT THE OFFERS - SUMMARY
The following summary provides only a limited overview of the Offers made under this Prospectus. Further
details are set out in this Prospectus. Please read and consider this Prospectus in full before making any decision
regarding seeking to accept the Offers or otherwise investing in the Company.
Topic
Summary
Placement Offer
What is the
Placement Offer?
An offer of an aggregate of 1,212,121,223 New Options to
subscribers for Shares under the Placement on the basis as
described in Section 1.1. The issue of these New Options was
approved by shareholders of the Company at the Meeting.
For more
information
see:
Sections 1.1
and 1.2
No funds will be raised under the Placement Offer.
What is the purpose
of the Placement
Offer?
The purpose of the Placement Offer is to facilitate the issue of the
New Options as approved by shareholders at the Meeting and, in
particular, to facilitate the secondary trading of Shares issued on
exercise of New Options, if any, and the secondary trading of New
Options if quotation (listing) of the New Options is granted by ASX.
Sections 1.2
and 2.
Who can apply under
the Placement Offer?
The Placement Offer is only made to and capable of acceptance by
subscribers for Shares under the Placement on the basis described
in Section 1.1. The Company will provide a personalised application
form to eligible investors to participate under the Placement Offer.
Sections 1.1
and 6
What are the terms of
New Options?
Each New Option has an exercise price of A$0.028 (2.8 Australian
cents), expiry date of 26 February 2027 and upon exercise entitle
the holder to one Share.
Sections
1.1, 1.2 and
9.1
The full terms of New Options are set out in Section 9.1.
Broker Offer
What is the Broker
Offer?
An offer of 10,179,688 New Options to MST Financial (and/or its
nominee(s)) as part fees for MST Financial acting as the lead
manager of the Placement as described in section 1.1. The issue of
the New Options was approved by shareholders at the Meeting.
Sections 1.1
and 1.2
No funds will be raised under the Broker Offer.
What is the purpose
of the Broker Offer?
The purpose of the Broker Offer is to facilitate the issue of the New
Options as approved by shareholders at the Meeting and, in
particular, to facilitate the secondary trading of Shares issued on
exercise of New Options, if any, and the secondary trading of New
Options if quotation (listing) of the New Options is granted by ASX.
Sections 1.2
and 2.
Who can apply under
the Broker Offer?
The Broker Offer is only made to and capable of acceptance by MST
Financial (and/or its nominee(s)). The Company will provide a
personalised application form to eligible investors to participate
under the Broker Offer.
Sections 1.1
and 6
-8Topic
Summary
What are the terms of
New Options?
Each New Option has an exercise price of A$0.028 (2.8 Australian
cents), expiry date of 26 February 2027 and upon exercise entitle
the holder to one Share.
For more
information
see:
Sections
1.1, 1.2 and
9.1
The full terms of New Options are set out in Section 9.1.
General
Are there risks
associated with
investment in the
Company?
There are risks associated with investment in the Company. These
include risks relating to the New Options, risks relating to the
Company and risks associated with financial investment generally.
Please carefully consider the risks and the information contained in
this Prospectus in conjunction with any specific matters which have
or may be referred to in the Company’s ASX announcements
(www.asx.com.au, search code “ATH”) before applying for or
acquire New Options or otherwise investing in the Company.
Section 5
What are the taxation
implications of
receiving New
Options?
Taxation implications will vary depending upon the specific
circumstances of the investor. You should obtain professional
advice as to the taxation treatment applicable to you.
Section 11
Where can I find more
information?
For more information on the Company please see the Company's
website (www.alteritytherapeutics.com) or the Company’s ASX
announcements (available on the ASX's website www.asx.com.au,
search code “ATH”).
Sections 7,
8 and 17
What if I have
questions?
You should consult your stockbroker, accountant, solicitor or other
professional adviser before deciding to apply for Options.
Section 17
Questions concerning the Offers can be directed to the Company by
email to: info@alteritytherapeutics.com.
-91.
Details of the Offers
1.1
The Offers
The New Options are offered as follows:
•
1,212,121,223 New Options are offered under the Placement Offer for issue to participants in the
Placement (described in Section 1.2) as free-attaching to Shares issued under the Placement on the basis
of one New Option for every three Shares issued under the Placement; and
•
10,179,688 New Options are offered under the Broker Offer to MST Financial (and/or its nominee(s)) as
part fees for MST Financial acting as lead manager of the Placement.
The issue of the offered New Options was approved by the shareholders of the Company at the Meeting on 31
March 2025.
Each of the Offers is only made to and capable of acceptance by the respective identified parties. The Company
will provide a personalised application form to identified parties to participate in the Offers (or either of them).
1.2
Background – Placement
On 10 February 2025, the Company announced it had received binding commitments for a capital raising of
A$40 million before costs via a placement of an aggregate of 3,636,363,636 Shares at an issue price of A$0.011
(1.1 Australian cents) per Share (Placement).
Under the terms of the Placement, every three Shares are to be accompanied by one New Option, subject to
shareholder approval for the issue of New Options which was obtained at the Meeting. The issue of the New
Options as free-attaching to Shares under the Placement is the subject of the Placement Offer.
The full terms of the New Options are set out in Section 9.1.
Participants in the Placement were sophisticated, professional and other investors exempt from the disclosure
requirements of Chapter 6D of the Corporations Act. The participants in the Placement included unrelated
investors who are clients of MST Financial, unrelated Australian and international institutions, unrelated
investors that were identified by the Company as part of its investor relations program and the Directors of the
Company.
Issue of the Shares under the Placement was completed in two tranches as described below:
•
1,165,841,830 Shares were issued on 17 February 2025 under the placement capacity available to the
Company under ASX Listing Rule 7.1 (799,014,703 Shares) and ASX Listing Rule 7.1A (366,827,127 Shares)
in combination, raising approximately A$12.8 million before costs; and
•
The issue of 2,470,521,806 Shares was subject to shareholder approval, which was received at the
Meeting. These Shares were issued on 4 April 2025, raising approximately A$27.2 million before costs.
MST Financial acted as lead manager of the Placement. The fees payable to MST Financial (and/or its
nominee(s)) comprise:
•
5.5% of the amount raised up to A$30 million under the Placement; and
•
6% of the amount raised above A$30 million under the Placement; and
•
One New Option for every $2 raised under the Placement, up to a maximum of 10,179,688 New Options,
subject to shareholder approval for the issue of New Options (which was obtained at the Meeting). The
issue of these New Options to MST Financial (and/or its nominee(s)) is the subject of the Broker Offer.
- 10 1.3
ASX Listing – New Options
The Company proposes seeking quotation (listing) of issued New Options. New Options will be unquoted
(unlisted) unless and until such time as the Company satisfies the quotation requirements of ASX, which will
include:
•
There being at least 100,000 New Options on issue; and
•
The New Options being held by at least 50 holders with a marketable parcel (being if all options held
by the holder are exercised in full, the underlying ordinary Shares would be a parcel of not less than
$500 based on the trading price of Shares or the exercise price if underlying Shares are unquoted).
If official quotation of New Options is not granted, the New Options will be unlisted securities and will not be
tradeable on ASX. The fact ASX may grant official quotation of New Options is not to be taken as an indication
of the merits of the Company or the New Options. Appendix 3Bs released to ASX on 10 February 2025 and 24
February 2025 applied for quotation of New Options if the quotation requirements of ASX are satisfied.
For the avoidance of doubt, quotation of New Options is not a condition of the Offers (or either of them).
2.
Purpose of the Offers and this Prospectus
The purpose of this Prospectus and the Offers is to facilitate the issue of the New Options, in particular, to
facilitate the secondary trading of Shares issued on exercise of the New Options (if any) and, subject to
achieving quotation (listing), the secondary trading of the New Options on ASX, and to implement the
shareholder approval for the issue of the New Options as received at the Meeting.
3.
Financial effect of the Offers
No funds will be raised under the Offers and accordingly the only impact of the Offers will be to reduce the
cash reserves of the Company by the costs of the Offers. Estimated, approximate anticipated costs of the Offers
are set out below:
Particulars
Amount ($)
Legal, printing and postage
$13,000
ASIC & ASX fees*
$50,000
TOTAL
$63,000
*Assumes quotation of all the New Options
4.
Effect on Control and the Capital Structure of the Company
4.1
Capital Structure
SHARES
The Offers will not impact the issued Share capital of the Company unless and until New Options are exercised
into Shares (if any). There is no guarantee that a certain number of New Options will be exercised into Shares,
or any at all. For indicative purposes, the below tables show the impact of the exercise of 50% and 100% of the
New Options under the Offers on the issued Share capital of the Company:
- 11 Number
%
Existing Shares
9,127,370,686
93.72%
Shares issued on exercise of 50% of New Options under the Offers
611,150,456
6.28%
Total Shares post New Option exercise
9,738,521,142
100%
Number
%
Existing Shares
9,127,370,686
88.19%
Shares issued on exercise of 100% of New Options under the Offers
1,222,300,911
11.81%
Total Shares post New Option exercise
10,349,671,597
100%
Notes to tables:
1.
All percentages are subject to rounding.
2.
The number of New Options exercised as described in the tables above are indicative only. There is no
guarantee that a certain number of New Options will be exercised into Shares, or any at all.
OPTIONS
The existing and proposed options of the Company are set out in the table below. All existing options other
than the ATHO options are unlisted, however, the Company proposes seeking quotation (listing) of the Options.
The quotation (listing) of the Options is not a condition of the Offers (or either of them):
ASX code
Number of options
Expiry Date
Exercise price
ATHAAB
35,000,000
17 September 2025
$0.09 (9 cents)
ATHAAD
91,392,720
6 January 2026
$0.032 (3.2 cents)
ATHO
932,611,269
31 August 2026
$0.01 (1 cent)
ATHAAE
14,250,000
29 November 2026
$0.0375 (3.75 cents)
ATHAAG
11,900,000
29 November 2026
$0.0238 (2.38 cents)
ATHAAH
8,000,000
19 December 2026
$0.0105 (1.5 cents)
ATHAAK
170,000,000
30 December 2027
$0.01 (1 cent)
ATHAB
62,500,000
13 March 2029
US$0.0031 (0.31 US cents)
ATHAA
20,166,667
13 March 2029
US$0.004 (0.4 US cents)
ATHAC
120,000,000
21 March 2029
US$0.003 (0.3 US cents)
New Options under the
Placement Offer
1,212,121,223
26 February 2027
$0.028 (2.8 cents)
New Options under the
Broker Offer
10,179,688
26 February 2027
$0.028 (2.8 cents)
4.2
Details of substantial holders
As at the date of this Prospectus, the Company has received notices from two substantial shareholders (being
holders of a relevant interest in 5% of more of the Shares on issue), being:
- 12 •
the Bank of New York Mellon Corporation and each Group Entity that together form the BNYMC Group,
as holding a relevant interest in 2,277,309,274 Shares (approximately 24.95%). BNYMC Group has
advised that the relevant interest in 2,277,308,548 shares arises from the BNYMC Group having the
limited power to dispose of, or control exercise of power to dispose of, securities deposited with or held
by BNYMC (or its custodian or agent) in its capacity as depositary administering an American depository
receipts (ADR) program for the Company. BNYMC Group does not have voting power in respect of those
Shares.
•
Regal Funds Management Pty Ltd and its associates as holding a relevant interest in 1,255,948,179
Shares (approximately 13.76%).
Issue of New Options will not impact the relevant interests shareholders, including substantial shareholders.
4.3
Dilution and control
The existing percentages shareholdings in the Company of shareholders will not be diluted from issue of New
Options under the Offers, are the New Options are convertible securities that do not have voting rights unless
and until exercised into Shares. Accordingly, the Offers will not (collectively or in isolation) have a material
impact on the control (as defined by section 50AA of the Corporations Act) of the Company.
The percentage shareholdings in the Company of shareholders may be diluted following the issue of Shares (if
any) upon exercise of New Options. For indicative purposes, if the Offers are fully subscribed and all New
Options are exercised then 1,222,300,911 Shares will be issued (subject to rounding) and if the Offer is 50%
subscribed and those New Options are exercised then 611,150,456 Shares (subject to rounding) will be issued.
The dilutive impact of the exercise of 50% or all New Options under the Offers is set out in the table below:
Shareholder
(example)
Holding
% at date of this
Prospectus
As % of total Shares if
50% of New Options
exercised
As % of total Shares if
100% of New Options
exercised
A
10,000,000
0.11%
0.10%
0.10%
B
25,000,000
0.27%
0.26%
0.24%
C
50,000,000
0.55%
0.51%
0.48%
D
150,000,000
1.64%
1.54%
1.45%
300,000,000
3.29%
3.08%
2.90%
Notes to Table:
•
All percentages are rounded to two decimal places.
•
Assumes the percentage of New Options that are issued under the Offers are exercised into Shares. The above table is
indicative only and there is no guarantee a certain number of, or any, New Options will be exercised into Shares.
•
It is assumed the notional Shareholders in the example above do not acquire or dispose of Shares.
•
The above does not take into account the exercise of any options except as stated otherwise.
5.
Risks
New Options are considered highly speculative. An investment in the Company carries risk.
The Directors strongly recommend potential investors consider the risk factors described below, together with
information contained elsewhere in the Prospectus.
This section identifies circumstances the Directors regard as risks associated with investment in the Company and
which may have a material adverse impact on the financial performance of the Company if they were to arise.
- 13 Specifically:
•
the Offers and New Options are subject to specific risks (refer to Section 5.1); and
•
the business, assets and operations of the Company are subject to further risk factors. The Company
provided detailed disclosure of business risk factors in item 3.D of its 2024 Annual Report for the
reporting period ended 30 June 2024 that was released to ASX on 26 September 2024. The 2024 Annual
Report has been lodged with ASIC and item 3.D of 2024 Annual Report is incorporated by reference
into this Prospectus in accordance with Section 712 of the Corporations Act.
A copy of item 3.D of the 2024 Annual Report is available at www.asx.com.au (search code “ATH”) and
can be obtained from the Company upon request. A selection of the risk factors as contained in item
3.D of the 2024 Annual Report are set out in Section 5.2.
Where possible, the Directors aim to manage these risks by carefully planning the Company’s activities and
implementing risk control measures. However, some of the risks identified are highly unpredictable or are out of
the control of the Company and the Company is therefore limited to the extent it can effectively manage them.
These risk factors are not intended
Share your feedback
Discover